Microdosing is the practice of consuming sub-perceptual doses of a psychoactive substance — typically 5–10% of a standard dose — to explore subtle cognitive, mood, and energy effects without full psychoactive impairment, though the largest placebo-controlled study to date found most benefits track expectation rather than pharmacology.
The largest placebo-controlled microdosing study to date — a 2021 self-blinding citizen-science trial with 191 participants — found that people who believed they'd taken a psychedelic reported greater wellbeing and lower anxiety than those who believed they'd taken placebo, regardless of what they'd actually taken, with no statistically significant difference between the real and placebo groups on most outcomes (Szigeti et al., eLife, 2021). Amanita muscaria microdosing works through a different mechanism than psilocybin or LSD: its active compound, muscimol, is a GABA-A receptor agonist rather than a serotonin receptor agonist, which is why users describe a calming, grounding effect rather than the perceptual shifts associated with classic psychedelics. Proper drying is essential — it doesn't simply "remove" the mushroom's more irritating ibotenic acid, but partially converts it to muscimol, with published research showing the exact ratio depends heavily on drying method and temperature (Tsunoda et al., 1993).
What Is Microdosing and Why Are People Interested?
Microdosing means taking sub-perceptual amounts of a psychoactive substance — small enough that they don't produce a full intoxicating effect. The concept has moved from niche wellness communities into broader conversations about mental performance, emotional wellbeing, and neurological research, with professionals, artists, and people managing mental health challenges all reporting experimentation with microdosing protocols.
What the Best Controlled Research Actually Found
Most public discussion of microdosing draws on anecdote, but one study changed that. In 2021, researchers ran the largest placebo-controlled psychedelic microdosing study to date using a self-blinding citizen-science design: participants prepared their own identical-looking psychedelic and placebo capsules at home, without knowing which was which, and tracked outcomes via an app (Szigeti et al., eLife, 2021).
The result was a genuine surprise to many microdosing advocates. Both the microdose group and the placebo group showed statistically significant improvements in wellbeing — but there was no significant difference between the two groups on almost every outcome measured. What did predict how good someone felt was their belief about which substance they'd taken, not which substance they'd actually taken. That's a strong signal that expectancy effects account for much of what people attribute to microdosing itself.
This doesn't mean microdosing "doesn't work" in a simple sense — participants in both arms did report real improvements. It means the mechanism driving those improvements, at least for classic psychedelics in this study design, appears to be substantially psychological rather than pharmacological. That's an important caveat to sit alongside any specific compound's individual pharmacology, including Amanita muscaria's.
How Amanita Muscaria Microdosing Differs from Psilocybin
Amanita muscaria works through a genuinely different mechanism than psilocybin mushrooms, which is relevant given the finding above. While psilocybin acts on serotonin 5-HT2A receptors, Amanita muscaria's primary active compound, muscimol, binds to GABA-A receptors — the brain's main inhibitory neurotransmitter system. That's a pharmacologically distinct target, and it's consistent with why Amanita microdosing tends to produce a calming, grounding effect rather than the perceptual shifts associated with classic serotonergic psychedelics.
Because the mechanism differs, the Szigeti findings on psilocybin/LSD expectancy effects don't automatically transfer one-to-one to Amanita — but they're still a useful reminder to track your own response carefully rather than assume a specific outcome in advance.
Potential Effects Reported by Amanita Microdosers
People practicing Amanita microdosing commonly report reduced anxiety and racing thoughts, improved sleep quality, easier attention-shifting between tasks, a quieter inner mental environment, and a sense of emotional stability through the day. These reported effects are broadly consistent with what low-level GABAergic modulation would be expected to produce.
It's worth being direct about the evidence status: most of this is still anecdotal, and formal clinical research specifically on Amanita microdosing remains limited, unlike the psilocybin/LSD literature where at least the large citizen-science trial above exists. Interest from the research community is growing as legal and regulatory barriers in several regions ease, but the same expectancy caveat that applies to classic psychedelics is a reasonable one to keep in mind here too.
Preparation Matters More Than People Assume
A typical Amanita microdose protocol starts with very small amounts — often around 0.1 g of dried, properly prepared material — taken on a schedule with days off to limit tolerance buildup. Preparation method matters significantly and is more nuanced than "drying removes the bad part": published research tracking ibotenic acid and muscimol content through drying, storage, and cooking found that drying converts a meaningful portion of ibotenic acid to muscimol, but the exact proportion depends on drying method and temperature, and some ibotenic acid reliably remains even in well-dried material (Tsunoda et al., J Food Hyg Soc Jpn, 1993). The same research found muscimol concentration increases further during acidic heat-cooking, more so than under alkaline conditions.
The practical takeaway is that "dried" isn't a single, uniform state — different drying and preparation methods yield meaningfully different ibotenic acid-to-muscimol ratios, which is a real source of the batch-to-batch variability people report. Starting low, using a consistently sourced extract or tincture, and increasing gradually only after observing your own response over several sessions are the practical guardrails that matter most given that variability. Avoid combining Amanita with alcohol, benzodiazepines, or other GABAergic substances, since the additive GABA-A effect can compound sedation unpredictably.
Building a Structured Self-Assessment
Given how strongly expectancy shaped outcomes in the controlled psilocybin/LSD research, the most useful thing an individual microdoser can do is build some structure into their own tracking rather than relying purely on how a given day "felt." A simple daily log — mood, sleep quality, focus, and any physical sensations, recorded before you know how the day will go — makes it easier to separate a genuine week-over-week pattern from a single good or bad day you'd naturally attribute to the practice either way.
Sticking to a defined trial period (four to eight weeks is common) with clear days off, rather than adjusting the dose reactively day to day, also reduces the temptation to chase a feeling by escalating the amount — which pushes you out of the sub-perceptual range the whole practice depends on.
Who Should Be More Cautious
Microdosing isn't a good fit for everyone, and Amanita's specific GABA-A mechanism adds its own considerations. Anyone already taking benzodiazepines, other GABAergic medications, or alcohol regularly should be especially cautious, since the additive sedative effect is harder to predict than either substance alone. People with a personal or family history of psychosis are generally advised to avoid psychoactive substances of any kind, including sub-perceptual doses, given how limited the safety research still is. Pregnant or breastfeeding individuals, and anyone on medication with a narrow safety margin, should treat this as an area to discuss with a healthcare provider first rather than experiment with independently.
Legal and Regulatory Status
Amanita muscaria is legal in most European countries and the United States, unlike psilocybin mushrooms, which remain controlled substances in many jurisdictions. That legal accessibility makes it an appealing option for people curious about a functional-mushroom approach to wellbeing who want to stay within clear legal boundaries. Legal status still varies by country, so confirming local regulations before purchasing or using any Amanita product is worth the five minutes it takes.
You can also buy them in our store.
1. Amanita fruits
2. Amanita capsules
3. Amanita extract
4. Mushroom ground
Frequently Asked Questions
Does microdosing actually work, or is it mostly placebo?
The largest placebo-controlled study to date found both real-dose and placebo groups improved similarly, with belief about which substance was taken predicting outcomes better than the actual substance did (Szigeti et al., 2021). That's a meaningful expectancy effect, though it doesn't rule out any pharmacological contribution entirely.
How is Amanita muscaria microdosing different from psilocybin microdosing?
Amanita's active compound, muscimol, is a GABA-A receptor agonist, while psilocybin acts on serotonin receptors. That mechanistic difference is why Amanita tends to produce a calming, grounding effect rather than the perceptual shifts of classic psychedelics.
Does drying remove all the ibotenic acid from Amanita muscaria?
No. Drying converts a meaningful portion of ibotenic acid to muscimol, but the exact ratio depends on drying method and temperature, and some ibotenic acid typically remains even in well-dried material (Tsunoda et al., 1993).
What's a typical starting Amanita microdose?
Many protocols start around 0.1 g of dried, properly prepared material, taken on a schedule with days off, increasing only gradually after observing your own response over several sessions.
Is Amanita muscaria legal for microdosing?
It's legal in most European countries and the United States, unlike psilocybin, but legal status varies by country, so confirm local regulations before purchasing or using any product.
Related Articles
- Amanita Muscaria Microdosing: Benefits and Risks
- Fly Agaric Microdosing for ADHD: Results
- Microdosing vs Antidepressants
Sources
- Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878. PMC7925122
- Tsunoda K, Inoue N, Aoyagi Y, Sugahara T. Change in ibotenic acid and muscimol contents in Amanita muscaria during drying, storing or cooking. J Food Hyg Soc Jpn. 1993;34(2):153-160. J-STAGE
- Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycological Research. 2003. PMID 12733432